Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MNPRthis companyMonopar Therapeutics Inc.	$72.70	-35.3×	3.51×	0×	-30.78×	-87.9%	0.0%	0.0%	0.0%	-10.0%	-12.1%	-2.5%	0×	4.5×	0×	51.35×	0.0%	0	64.41	2	C
ALXOALX Oncology Holdings Inc.	$1.23	-0.59×	2.33×	0×	-0.5×	-90.6%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-2.66	2	C
ATNMActinium Pharmaceuticals, Inc.	$1.60	-1.25×	5.42×	471.4×	0.12×	0.8%	100.0%	-40274.4%	-37652.2%	-432.6%	-81.4%	-58.2%	0.22×	1.4×	0×	6.2×	0.0%	4	-8.02	5	S-
CMPXCompass Therapeutics, Inc.	$0.80	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
IMNMImmunome, Inc.	$19.14	-8.84×	2.96×	270.32×	-5.86×	-62.3%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	31.88	2	C+
MGNXMacroGenics, Inc.	$2.47	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-1.36×	2.96×	0.68×	-2.54×	-84.0%	57.4%	-48.7%	-49.9%	-134.2%	-35.3%	-58.2%	0.2×	0.32×	0×	6.2×	0.0%	2	-2.66	2	—